"Opponents of this new warning label believe it represents a measure that is not fully thought out. They believe adequate safety protocols have already been in place, and that the new label may scare off women and their doctors from medications they need to manage anxiety or depression. A decision on whether to add the warning label is expected soon."
"On July 21 of this year, experts from around the world convened at the U.S. Food and Drug Administration (FDA) headquarters outside Washington, DC to debate whether a "black box" warning label should be added to antidepressants when taken by women during pregnancy. Opponents of this new warning label believe it represents a measure that is not fully thought out."
Experts convened at the FDA headquarters to debate adding a "black box" warning label to antidepressants used during pregnancy. Proponents argue selective serotonin reuptake inhibitors (SSRIs) pose significant birth-defect risks to the developing fetus and sometimes risks to the mother, prompting consideration of a stricter warning. Opponents contend the measure is not fully thought out, that existing safety protocols suffice, and that a stronger label could deter women and clinicians from necessary treatment for anxiety or depression. A decision is expected soon. Coordination between obstetrics/gynecology and behavioral health providers is necessary to protect mothers and infants.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]